FTC Deepens Probe Into Cencora's Vet Unit Merger With Covetrus
COR sits 26% above its 52-week low of $244.82.
Summary
The FTC is intensifying its review of the merger between Covetrus and Cencora's MWI Animal Health, signaling potential antitrust concerns. This is the first indication of regulatory pushback on the deal, which could delay or block the combination of two major veterinary product distributors. Cencora, with a market cap near $60 billion, faces uncertainty around a strategic unit that contributes to its animal health segment. The news follows a period of strong financial performance and a raised guidance, but this regulatory hurdle introduces a new risk. No specific timeline for the FTC's decision has been disclosed.
At the time of this announcement, COR was trading at $307.95 on NYSE in the Life Sciences sector, with a market capitalization of approximately $59.9B. The 52-week trading range was $244.82 to $377.54. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.